News >

Targeted Treatments Usher in Individualized Care in mCRC

Caroline Seymour
Published: Monday, Apr 15, 2019

Jonathan Mizrahi, MD

Jonathan Mizrahi, MD

The standard of care for patients with metastatic colorectal cancer (mCRC) can continued to be improved through better use of molecular testing, explained Jonathan Mizrahi, MD.

As more molecular subsets are defined, and additional targeted therapies are developed, the importance of understanding the underlying genomic makeup of a patient’s tumor is becoming increasingly important.

Two examples of this research focus were presented at the 2019 Gastrointestinal Cancers Symposium, both of which confirmed the benefit of targeted therapy for patients with identifiable genomic abnormalities, such as BRAF V600E–mutant and microsatellite stable (MSS) disease. Updated results from the safety lead-in portion of the phase III BEACON CRC trial showed that the combination of encorafenib (Braftovi), binimetinib (Mektovi), and cetuximab (Erbitux) induced a high objective response rate (ORR) of 48% in patients with BRAF V600E–mutant mCRC by local assessment, surpassing historical ORRs of <10%.1

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication